Keros Therapeutics (NASDAQ:KROS) Rating Lowered to “Market Perform” at William Blair

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, Marketbeat.com reports.

Several other analysts also recently commented on the stock. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Scotiabank initiated coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective on the stock. Bank of America decreased their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Finally, Guggenheim reiterated a “buy” rating and issued a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.67.

Keros Therapeutics Stock Up 2.2 %

KROS stock opened at $18.83 on Thursday. The firm has a market cap of $762.75 million, a price-to-earnings ratio of -3.61 and a beta of 1.20. The company’s fifty day simple moving average is $59.11 and its 200 day simple moving average is $52.63. Keros Therapeutics has a 12-month low of $15.67 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter last year, the company earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Research analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently bought and sold shares of KROS. KBC Group NV lifted its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the third quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP bought a new stake in Keros Therapeutics in the 3rd quarter worth about $213,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.